Announcements Trials
Browse Landscape

Phase

Phase 3 7Phase 1 5Phase 1/2 3Phase 2 1

Status

Unknown 2Recruiting 1

Sponsor Class

OTHER 5INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Breast 1

Conditions

HER2-expressing Advanced Solid Tumors 1HER2 Positive Metastatic Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × pyrotinib × Clear all
NCT06015048 2024-08-05

A Trial of SHR-A1811 Combined With Other Antitumor Therapies in Advanced Solid Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
364 enrolled
Other solid neoplasm

HER2-expressing Advanced Solid Tumors

NCT05745740 2023-11-27

A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

RemeGen Co., Ltd.

Phase 1/2 Unknown
26 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02422199 2018-07-09

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Unknown
128 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡